Pathological gambling in Parkinson's disease: Disease related or drug related?

Expert Review of Neurotherapeutics

Volumn 11, Issue 6, 2011, Pages 809-814

  Calandrella, Daniela ^a   Antonini, Angelo ^a,b  

^a Clinic San Pio X   (Italy)

^b IRCSS San Camillo   (Italy)

Author keywords

dopamine agonists; frontal lobe; levodopa; Parkinson's disease; pathological gambling

Indexed keywords

APOMORPHINE; ARIPIPRAZOLE; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; GLUTAMATE RECEPTOR; LEVODOPA; PRAMIPEXOLE; RACLOPRIDE C 11; ROPINIROLE; SEROTONIN TRANSPORTER;

BRAIN SCINTISCANNING; COMPULSIVE PERSONALITY DISORDER; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; EXECUTIVE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; IMPULSIVENESS; NEUROBIOLOGY; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; REVIEW; REWARD; SCHIZOPHRENIA;

ANTIPARKINSON AGENTS; GAMBLING; HUMANS; PARKINSON DISEASE;

EID: 79958248407     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.70     Document Type: Review

References (58)

1. Potenza MN, Kosten TR, Rounsaville BJ. Pathological gambling. JAMA 286, 141-144 (2001). (Pubitemid 32640836)
2. Single E. Estimating the costs of substance abuse: implications to the estimation of the costs and benefits of gambling. J. Gambl. Stud. 19(2), 215-233 (2003). (Pubitemid 39024155)
3. American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders (4th Edition). American Psychiatric Association, Washington, DC, USA (2000).
4. WHO. WHO International Statistical Classification of Diseases and Related Health Problems (10th Revision) (2003).
5. Dagher A, Robbins TW. Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 61(4), 502-510 (2009).
6. Lader M. Antiparkinsonian medication and pathological gambling. CNS Drugs 22(5), 407-416 (2008). (Pubitemid 351508124)
7. Voon V, Fernagut PO, Wickens J, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol. 8(12), 1140-1149 (2009).
8. Frank MJ, Seeberger LC, O'Reilly RC. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 306(5703), 1940-1943 (2004). (Pubitemid 39627859)
9. Bódi N, Kéri S, Nagy H, et al. Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain 132(Pt 9), 2385-2395 (2009).
10. Cilia R, Siri C, Marotta G, et al. Functional abnormalities underlying pathological gambling in Parkinson disease. Arch. Neurol. 65(12), 1604-1611 (2008).
11. Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 132(Pt 5), 1376-1385 (2009).
12. Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. Drug Saf. 32(6), 475-488 (2009).
13. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch. Neurol. 63(7), 969-973 (2006). (Pubitemid 44036299)
14. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67(7), 1254-1257 (2006). (Pubitemid 44563838)
15. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch. Neurol. 62(9), 1377-1381 (2005). (Pubitemid 41352054)
16. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov. Disord. 22(12), 1757-1763 (2007). (Pubitemid 47597599)
17. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 67(5), 589-595 (2010).
18. Lu C, Bharmal A, Suchowersky O. Gambling and Parkinson disease. Arch. Neurol. 63(2), 298 (2006).
19. Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, Bonfa F. Prevalence of pathological gambling in patients with Parkinson's disease. Mov. Disord. 21, 2068-2072 (2006). (Pubitemid 46140413)
20. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J. Neurol. Neurosurg. Psychiatry 68(4), 423-428 (2000). (Pubitemid 30248740)
21. Ambermoon P, Carter A, Hall WD, Dissanayaka NN, O'Sullivan JD. Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction 106(2), 283-293 (2011).
22. Cohen J, Magalon D, Boyer L, Simon N, Christophe L. Aripiprazole-induced pathological gambling: a report of 3 cases. Curr. Drug Saf. 6(1), 51-53 (2011).
23. Antonini A, Siri C, Santangelo G, et al. Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. Mov. Disord. 26(3), 464-468 (2011).
24. Barns Neurauter MP, Rickards H, Cavanna AE. The prevalence and clinical characteristics of pathological gambling in Parkinson's disease: an evidence-based review. Funct. Neurol. 25(1), 9-13 (2010).
25. Edens EL, Rosenheck RA. Rates and correlates of pathological gambling among VA mental health service users. J. Gambl. Stud. DOI: 10.1007/s10899-011- 9239-z (2011) (Epub ahead of print).
26. Kennedy SH, Welsh BR, Fulton K, et al. Frequency and correlates of gambling problems in outpatients with major depressive disorder and bipolar disorder. Can. J. Psychiatry 55(9), 568-576 (2010).
27. Isaias IU, Siri C, Cilia R, De Gaspari D, Pezzoli G, Antonini A. The relationship between impulsivity and impulse control disorders in Parkinson's disease. Mov. Disord. 23(3), 411-415 (2008).
28. Lorains FK, Cowlishaw S, Thomas SA. Prevalence of comorbid disorders in problem and pathological gambling: systematic review and meta-analysis of population surveys. Addiction 106(3), 490-498 (2011).
29. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic medication-related pathological gambling in Parkinson disease. Arch. Neurol. 64(2), 212-216 (2007).
30. Siri C, Cilia R, De Gaspari D, et al. Cognitive status of patients with Parkinson's disease and pathological gambling. J. Neurol. 257(2), 247-252 (2010).
31. Ledgerwood DM, Orr ES, Kaploun KA, et al. Executive function in pathological gamblers and healthy controls. J. Gambl. Stud. DOI: 10.1007/s10899-010-9237-6 (2011) (Epub ahead of print).
32. Rissling I, Geller F, Bandmann O, et al. Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting 'sleep attacks'. Mov. Disord. 19(11), 1279-1284 (2004) (Pubitemid 39534543)
33. Kaiser R, Hofer A, Grapengiesser A, et al. l-DOPA-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 60(11), 1750-1755 (2003). (Pubitemid 36737068)
34. Lee JY, Lee EK, Park SS, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov. Disord. 24(12), 1803-1810 (2009).
35. Eisenegger C, Knoch D, Ebstein RP, Gianotti LR, Sándor PS, Fehr E. Dopamine receptor D4 polymorphism predicts the effect of L-DOPA on gambling behavior. Biol. Psychiatry 67(8), 702-706 (2010).
36. Slutske WS, Zhu G, Meier MH, Martin NG. Genetic and environmental influences on disordered gambling in men and women. Arch. Gen. Psychiatry 67(6), 624-630 (2010).
37. Marinelli M, White FJ. Enhanced vulnerability to cocaine self-administration is associated with elevated impulse activity of midbrain dopamine neurons. J. Neurosci. 20(23), 8876-8885 (2000).
38. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol. 2(10), 595-604 (2003). (Pubitemid 37162568)
39. Basar K, Sesia T, Groenewegen H, Steinbusch HW, Visser-Vandewalle V, Temel Y. Nucleus accumbens and impulsivity. Prog. Neurobiol. 92(4), 533-557 (2010).
40. Ouchi Y, Yoshikawa E, Okada H, et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for b-CFT binding with positron emission tomography. Ann. Neurol. 45, 601-610 (1999). (Pubitemid 29217588)
41. Schultz W, Dayan P, Read Montague P. A neural substrate of prediction and reward. Science 275, 1593-1599 (1997). (Pubitemid 27120526)
42. Girault JA, Greengard P. The neurobiology of dopamine signaling. Arch. Neurol. 61(5), 641-644 (2004). (Pubitemid 38637678)
43. Künig G, Leenders KL, Martin-Sölch C, Missimer J, Magyar S, Schultz W. Reduced reward processing in the brains of Parkinsonian patients. Neuroreport 11(17), 3681-3687 (2000).
44. Kulisevsky J, Avila A, Barbanoj M, Berthier ML, Gironell A. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 119, 2121-2132 (1996). (Pubitemid 27032641)
45. Cools R. Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease. Neurosci. Biobehav. Rev. 30(1), 1-23 (2006). (Pubitemid 41779404)
46. Voon V, Pessiglione M, Brezing C, et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 65(1), 135-142 (2010).
47. Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF. Variation in dopamine genes influences responsivity of the human reward system. Proc. Natl Acad. Sci. USA 106(2), 617-622 (2009).
48. Cilia R, Ko JH, Cho SS, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol. Dis. 39(1), 98-104 (2010).
49. Antonelli F, Ray N, Strafella AP. Imaging cognitive and behavioral symptoms in Parkinson's disease. Expert Rev Neurother. 10(12), 1827-1838 (2010).
50. van Eimeren T, Ballanger B, Pellecchia G, Miyasaki JM, Lang AE, Strafella AP. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology 34(13), 2758-2766 (2009).
51. Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 68(4), 301-303 (2007). (Pubitemid 46148346)
52. Evans AH, Butzkueven H. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov. Disord. 22(4), 590-591 (2007). (Pubitemid 46608168)
53. Abler B, Hahlbrock R, Unrath A, Grön G, Kassubek J. At-risk for pathological gambling: imaging neural reward processing under chronic dopamine agonists. Brain 132(9), 2396-2402 (2009).
54. van Eimeren T, Pellecchia G, Cilia R, et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 75(19), 1711-1716 (2010).
55. Cilia R, Cho SS, van Eimeren T, et al. Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov. Disord. 26(2), 225-233 (2011).
56. Vitale C, Santangelo G, Trojano L, Verde F, Rocco M, Grossi D, Barone P. Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson's disease. Mov. Disord. 26(5), 830-836 (2011).
57. Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol. 8(10), 929-937 (2009).
58. Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann. Neurol. 68(3), 400-404 (2010).